The second edition of Metamersion, the cycle of artistic, scientific, technological and therapeutic immersive events of the Champalimaud Foundation, launches on December 15th with the programme Latent Spaces, taking place at the Champalimaud Warehouse, in the former warehouses of DocaPesca, in Lisbon, in a location that is also in a latent phase, and where the first steps towards the creation of a centre dedicated to Human Neuroecology and Digital Therapeutics are being taken.

To mark this date, we asked Marcelo Mendonça, neurologist and researcher from the Neuropsychiatry Unit and Neural Circuits Dysfunction Lab at the Champalimaud Foundation to provide an overview of Movement Disorders, their symptoms, diagnosis and treatments.

This course is promoted by Champalimaud Foundation's Fior Lab, integrated in the congento - Consortium for Genetically Tractable Organisms - initiatives.

The scientific programme will cover

- Protocols for preparation of human cancer cells for injection;
- Generation of zebrafish xenografts (microinjection in the perivitelline space);
- Metastatic assay;
- Protocols for immunofluorescence;
- Mounting xenografts for confocal imaging;
- Confocal session.

Venue

Champalimaud Center for the Unknown, Lisbon

A report, published last week (16 November) in The Lancet Oncology by an expert commission, under the title Key messages from European Groundshot – addressing Europe’s cancer research challenges: a Lancet Oncology Commission, analyses the current state of cancer research in Europe, identifies geographical and gender gaps (among others), and issues recommendations to rethink the priorities of European cancer research.

Fátima Cardoso, director of the Breast Unit at the Champalimaud Clinical Center/Champalimaud Foundation, is among the co-authors of the new report.